The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2024 | The role of microglia in the pathophysiology of ICANS following CD19 CAR-T therapy
Janaki Manoja Vinnakota, University of Freiburg, Breisgau, Germany, discusses an investigation into the role of microglia in the pathophysiology of immune effector cell-associated neurotoxicity syndrome (ICANS) in patients receiving CAR T-cell therapy. In microglia isolated from mice treated with CD19 CAR T-cell therapy, TAK1 and the p38 MAPK-pathway were identified as key mediators of ICANS, indicating that TAK1-inhibition may be a promising avenue for managing ICANS associated with CD19 CAR T-cell therapy. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
